[go: up one dir, main page]

ES2138594T3 - Agentes derivados de piridina e imidazol para enfermedades cardiovasculares. - Google Patents

Agentes derivados de piridina e imidazol para enfermedades cardiovasculares.

Info

Publication number
ES2138594T3
ES2138594T3 ES92906439T ES92906439T ES2138594T3 ES 2138594 T3 ES2138594 T3 ES 2138594T3 ES 92906439 T ES92906439 T ES 92906439T ES 92906439 T ES92906439 T ES 92906439T ES 2138594 T3 ES2138594 T3 ES 2138594T3
Authority
ES
Spain
Prior art keywords
alkyl
optionally
piridine
imidazole
chch3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92906439T
Other languages
English (en)
Inventor
Roger Peter Dickinson
Kevin Neil Dack
John Steele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of ES2138594T3 publication Critical patent/ES2138594T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Treating Waste Gases (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE DESCRIBEN LOS COMPUESTOS DE FORMULA (I) O UN ESTER BIOCALIFICABLE DE LOS MISMOS, UNA SAL FARMACEUTICAMENTE ACEPTABLE O AMBOS, EN DONDE R1,R2,R3 Y R4 SON CADA UNO SELECCIONADOS INDEPENDIENTEMENTE DE H O ALQUILO C1-C4; R5 ES (CH2)MSO2R6, (CH2)MNHSO2R6 O (CH2)NHCOR7; R6 Y R7 SON ALQUILO C1-C6, PERFLUOROALQUILO(CH2)N C1-C3, CICLOALQIL(CH2)N C3-C6, ARIL(CH2)N O HETEROARIL(CH2)N; O R6 E NR8R9; R8 ES H O ALQUILO C1-C4; R9 ES ALQUILO C1-C6, CICLOALQUIL(CH2)N C3-C6, ARIL(CH2)N O HETEROARIL(CH2); O R8 Y R9 JUNTOS CON EL ATOMO DE NITROGENO AL CUAL ESTAN ADJUNTOS FORMAN UN ANILLO HETEROCICLICO DE 5 A 7 MIEMBROS QUE PUEDE OPCIONALMENTE INCORPORAR UN DOBLE ENLACE CARBON-CARBON O UNA UNION ATOMICA SELECCIONADA DE O, S, NH, N(ALQUIL C1-C4) Y N(ALCANOIL C1C5), Y QUE PUEDE SER OPCIONALMENTE SUSTITUIDO CON UNO DE TRES SUSTITUYENTES INDEPENDIENTEMENTE SELECCIONADOS DE ALQUILO C2-C4 Y ALCOXI C1-C4, QUE PUEDEN OPCIONALMENTE SER BENZO-FISIONADOS; X E CH2, CHCH3, C(OH)CH3, C=CH2 U O; M ES 0 O 1; N ES 0, 1, 2 O3; Y HET ES PIRIMIDIL 3CON LA PREVISION DE CUANDO HET ES IMIDAZILIL-1 ENTONCES X ES CH2 O CHCH3.LOS COMPUESTOS SON INHIBIDORES DE SINTETASA A2 TROMOXANA COMBINADA Y ANTAGONISTAS DE ENDOPEROXIDO/A2 TROMBOXANA DE UTILIDAD EN EL TRATAMIENTO DE ENFERMEDADES EN LAS CUALES LA TOMBOXANA A2 ES UN AGENTE CAUSATIVO.
ES92906439T 1991-04-04 1992-03-17 Agentes derivados de piridina e imidazol para enfermedades cardiovasculares. Expired - Lifetime ES2138594T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919107043A GB9107043D0 (en) 1991-04-04 1991-04-04 Therapeutic agents

Publications (1)

Publication Number Publication Date
ES2138594T3 true ES2138594T3 (es) 2000-01-16

Family

ID=10692617

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92906439T Expired - Lifetime ES2138594T3 (es) 1991-04-04 1992-03-17 Agentes derivados de piridina e imidazol para enfermedades cardiovasculares.

Country Status (14)

Country Link
US (2) US5457118A (es)
EP (1) EP0579618B1 (es)
JP (1) JP3088015B2 (es)
AT (1) ATE185560T1 (es)
CA (1) CA2104456C (es)
DE (1) DE69230141T2 (es)
DK (1) DK0579618T3 (es)
ES (1) ES2138594T3 (es)
FI (2) FI104070B1 (es)
GB (1) GB9107043D0 (es)
GR (1) GR3032308T3 (es)
IE (1) IE921060A1 (es)
PT (1) PT100332B (es)
WO (1) WO1992017451A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9220137D0 (en) * 1992-09-23 1992-11-04 Pfizer Ltd Therapeutic agents
AU2044297A (en) * 1996-03-29 1997-10-22 Meiji Seika Kaisha Ltd. Novel heterocyclic compounds having platelet aggregation inhibitory effects
EP1080075B1 (en) * 1998-03-23 2004-08-11 Aventis Pharmaceuticals Inc. Piperididinyl and n-amidinopiperidinyl derivatives
JP4202250B2 (ja) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
US6722688B2 (en) 2001-11-21 2004-04-20 The Burton Corporation Snowboard binding system
JP2006514084A (ja) * 2002-12-03 2006-04-27 ヴェラ ファーマスーティカルズ インコーポレイテッド １−（３−ヒドロキシ−４−メトキシフェニル）−４−メチル−５−エチル−７，８−ジメトキシ−５ｈ−２，３−ベンゾジアゼピンの製薬組成物及びその用途
AU2003293405A1 (en) * 2002-12-03 2004-06-23 Vela Pharmaceuticals, Inc. Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof
US20070032479A1 (en) * 2003-12-03 2007-02-08 Leventer Steven M Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines
EP3827747A1 (en) 2005-04-28 2021-06-02 Otsuka Pharmaceutical Co., Ltd. Pharma-informatics system
US20080064729A1 (en) * 2006-09-07 2008-03-13 Millennium Pharmaceuticals, Inc. Phenethylamide derivatives with kinase inhibitory activity
CN101594878A (zh) 2006-09-18 2009-12-02 雷普特药品公司 通过给予受体相关蛋白（rap）-缀合物对肝病症的治疗
DK3395372T3 (da) 2009-02-20 2022-04-19 Enhanx Biopharm Inc System til afgivelse af glutathion-baseret medikament
CN110075069A (zh) 2009-05-06 2019-08-02 实验室护肤股份有限公司 包含活性剂-磷酸钙颗粒复合物的皮肤递送组合物及其应用
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60172964A (ja) * 1984-02-15 1985-09-06 Tanabe Seiyaku Co Ltd 桂皮酸誘導体及びその製法
US4837333A (en) * 1987-05-14 1989-06-06 G. D. Searle & Co. Substituted alkylidene imidazoles
DE3932403A1 (de) * 1989-05-12 1991-04-11 Thomae Gmbh Dr K Neue arylsulfonamide, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
IL94805A (en) * 1989-06-28 1994-04-12 Ciba Geigy Ag (Arylsulfonamido- and pyridyl- or imidazolyl-)-substituted carboxylic acids, processfor their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
PT100332B (pt) 1999-06-30
FI104070B (fi) 1999-11-15
EP0579618A1 (en) 1994-01-26
DK0579618T3 (da) 2000-01-03
DE69230141T2 (de) 2000-02-03
FI990179A7 (fi) 1999-02-01
FI104070B1 (fi) 1999-11-15
CA2104456A1 (en) 1992-10-05
US5705523A (en) 1998-01-06
US5457118A (en) 1995-10-10
FI934045A0 (fi) 1993-09-15
EP0579618B1 (en) 1999-10-13
IE921060A1 (en) 1992-10-07
FI990179A0 (fi) 1999-02-01
JPH06506200A (ja) 1994-07-14
DE69230141D1 (de) 1999-11-18
JP3088015B2 (ja) 2000-09-18
CA2104456C (en) 1996-12-10
WO1992017451A1 (en) 1992-10-15
GR3032308T3 (en) 2000-04-27
PT100332A (pt) 1993-07-30
ATE185560T1 (de) 1999-10-15
GB9107043D0 (en) 1991-05-22
FI934045A7 (fi) 1993-09-15

Similar Documents

Publication Publication Date Title
ES2138594T3 (es) Agentes derivados de piridina e imidazol para enfermedades cardiovasculares.
ECSP941102A (es) Pirazolopirimidinonas para el tratamiento de la impotencia
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
ES2092316T3 (es) Agentes antianginosos de purinona.
ES2114952T3 (es) Agentes antianginales derivados de quinazolinona.
PE49395A1 (es) Compuestos diazabiciclicos, antagonistas de neurocinina
AR036093A1 (es) Compuestos derivados de tiazolidinilo, pirrolidinilo, oxazolidinilo, piperidilo, morfolinilo y tiomorfolinilo, su uso, composiciones farmaceuticas que los comprenden, y compuestos intermediarios
ES2143238T3 (es) Derivados de 1-(piperidinil disustituido en posiciones 1,2)-piperazinas sustituidas en posicion 4.
CO5031253A1 (es) Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen
CO5251381A1 (es) Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen
CO5611152A2 (es) Compuestos derivados piperidina caracterizados por ser antagonistas del receptor de las taquicininas, especialmente del receptor nk1 y composiciones farmaceuticas que los contienen
DE69522945D1 (de) Verbindungen, die als antiproliferative mittel und als garft inhibitoren verwendbar sind
CO5150225A1 (es) Derivados del tetrahidropirano y su uso como agentes terapeuticos
ES2195933T3 (es) Nuevos derivados de flavonas, xantonas y cumarinas.
AR039988A1 (es) Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos
AR043487A1 (es) Heterociclos fusionados de pirimidina y usos de los mismos
AR005672A1 (es) Derivados de la distamicina, proceso para prepararlos, y su utilizacion como agentes antitumorales y antivirales.
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
DE69133295D1 (de) 3,9-diazabicyclo-[3.3.1]-nonanylderivate, verfahren und intermediate für ihre darstellung und sie enthaltende pharmazeutische zusammensetzungen
CO5040004A1 (es) 2-4-diamino-1,3,5-triazinas, su preparacion y empleo como herbicidas y fitorreguladores
CO5690598A2 (es) 6-[(sustituido)fenil]triazolopirimidinas como agentes anticancer
ES2106015T3 (es) Derivados de indol.
YU48399B (sh) Jedinjenja 7-acil-3-(supstituisanih karbamoiloksi) cefema i postupak za njihovo dobijanje
EA200401077A1 (ru) 2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b
AR029374A1 (es) Compuestos derivados de benceno, su utilizacion, un procedimiento para su preparacion y una composicion farmaceutica que los contiene

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 579618

Country of ref document: ES